Bringing transplantation tolerance into the clinic: Lessons from the ITN and RISET for the Establishment of Tolerance consortia

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 441-448

  Turka, Laurence A ^a,b   Wood, Kathryn ^c,d   Bluestone, Jeffrey A ^d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Immune Tolerance Network   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d RISET Network   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; immunosuppression; transplantation tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; BELATACEPT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; RAPAMYCIN; RITUXIMAB; SIPLIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL THERAPY; CHIMERA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FUTUROLOGY; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; IRRADIATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CANCER; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; NONMYELOABLATIVE CONDITIONING; OUTPATIENT DEPARTMENT; REVIEW; TRANSPLANTATION TOLERANCE; ALLOTRANSPLANTATION; ANIMAL; CLINICAL TRIAL (TOPIC); COOPERATION; GRAFT REJECTION; IMMUNOLOGY; INTERNATIONAL COOPERATION; MASS COMMUNICATION; REGISTER; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; REGISTRIES; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955205506     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833bd371     Document Type: Review

References (75)

1. Gudmundsdottir H, Turka LA. Transplantation tolerance: mechanisms and strategies? Semin Nephrol 2000; 20:209-216.
2. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001; 108:943-948.
3. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887-1895.
4. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402-2410.
5. Aradhye S, Turka LA. Will tolerance become a clinical reality? Am J Med Sci 1997; 313:310-314.
6. Bluestone JA, Matthews J. The Immune Tolerance Network: tolerance at the crossroads. Philos Trans R Soc Lond B Biol Sci 2001; 356:773-776.
7. Goldman M, Wood K. European research on cell and organ transplantation: towards novel opportunities? Transpl Int 2007; 20:1016-1019.
8. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a nonmyeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68:1767-1775.
9. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169:493-502.
10. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59:256-262.
11. Kimikawa M, Sachs DH, Colvin RB, et al. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64:709-716.
12. Helg C, Chapuis B, Bolle JF, et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994; 58:1420-1422.
13. Jacobsen N, Taaning E, Ladefoged J, et al. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 1994; 343:800.
14. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114:954-955.
15. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006; 6:2121-2133.
16. Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 2003; 76:297-305.
17. Mapara MY, Kim YM, Wang SP, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100:1903-1909.
18. Spitzer TR, McAfee SL, Dey BR, et al. Nonmyeloablative haploidentical stemcell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75:1748-1751.
19. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
20. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893-898.
21. Manilay JO, Pearson DA, Sergio JJ, et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66:96-102.
22. Andreola G, Chittenden M, Shaffer J, et al. T.32. Mechanisms of donorspecific unresponsiveness following loss of chimerism in recipients of haploidentical combined bone marrow/kidney transplantation. Clinical Immunology 2009; 131:S60-S160.
23. +T reg cells. J Exp Med 2006; 203:1701-1711.
24. Porcheray F, Putnam AL, Xu-Yu Z, et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 2009; 9:2126-2135.
25. Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol 2007; 68:645-651.
26. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74:1192-1194.
27. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64:124-135.
28. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63:1-6.
29. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702.
30. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-1616.
31. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5:1347-1353.
32. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76:120-129.
33. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80:1051-1059.
34. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92.
35. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465-474.
36. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409-2417.
37. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505-515; quiz A559-561.
38. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80:765-774.
39. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80:457-465.
40. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78:426-433.
41. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3:722-730.
42. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006; 19:885-892.
43. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9:1087-1098.
44. Fandrich F, Dresske B, Bader M, Schulze M. Embryonic stem cells share immune-privileged features relevant for tolerance induction. J Mol Med 2002; 80:343-350.
45. Fandrich F, Lin X, Chai GX, et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 2002; 8:171-178.
46. Fandrich F, Zhou X, Schlemminger M, et al. Future strategies for tolerance induction: a comparative study between hematopoietic stem cells and macrophages. Hum Immunol 2002; 63:805-812.
47. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptanceinducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21:728-741.
48. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21:742-754.
49. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance- inducing cells. Transpl Int 2008; 21:808-813.
50. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28:638-645.
51. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14:387-397.
52. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72:449-454.
53. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007; 17:114-119.
54. Donckier V, Sanchez-Fueyo A, Craciun L, et al. Induction of tolerance in solid organ transplantation: the rationale to develop clinical protocols in liver transplantation. Transplant Proc 2009; 41:603-606.
55. Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant 2008; 13:506-512.
56. Kadry Z, Mullhaupt B, Renner EL, et al. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 2003; 76:1003-1006.
57. Matthes-Martin S, Peters C, Königsrainer A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 2000; 96:3997-3999.
58. Ringden O, Söderdahl G, Mattsson J, et al. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 2000; 69:2043-2048.
59. Donckier V, Troisi R, Toungouz M, et al. Donor stem cell infusion after nonmyeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol 2004; 13:139-146.
60. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006; 12:1523-1528.
61. Donckier V, Craciun L, Lucidi V, et al. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. Transplantation 2009; 87:S91-S95.
62. Feng S, Ekong U, Lobritto S, et al. Immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study [abstract #189] Boston, Massachusetts, USA; American Transplant Congress; 30 May to 3 June, 2009.
63. Benitez C, Chandramoorthy HC, Fernandez LP, et al. AST Annual Scientific Exchange [abstract #8] Orlando, Florida, USA; December 3-6, 2009.
64. Martinez-Llordella M, Lozanno JJ, Puig-Pey L, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
65. Newell KA, Asare A, Kirk AD, et al. Characteristics of tolerant renal transplant recipients: evidence for a B-cell signature associated with tolerance. J Clin Invest 2010 [Epub ahead of print].
66. Sagoo P, Perucha E, Sawitzki B et al. Indices of tolerance: development of crossplatform biomarkers to detect renal transplant tolerance in man. J Clin Invest 2010 [Epub ahead of print].
67. +T cells/ FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81:398-407.
68. Valujskikh A, VanBuskirk AM, Orosz CG, Heeger PS. A role for TGFbeta and B cells in immunologic tolerance after intravenous injection of soluble antigen. Transplantation 2001; 72:685-693.
69. Deng S, Moore DJ, Huang X, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol 2007; 178:6028-6032.
70. Reichardt P, Dornbach B, Rong S, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007; 110:1519-1529.
71. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32:129-140.
72. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007; 104:15448-15453.
73. Halloran PF, Bromberg J, Kaplan B, Vincenti F. Tolerance versus immunosuppression: a perspective. Am J Transplant 2008; 8:1365-1366.
74. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007; 7:650-654.
75. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med 2005; 11:605-613.